News
GRFS
9.45
-1.36%
-0.13
Weekly Report: what happened at GRFS last week (0202-0206)?
Weekly Report · 1d ago
GRFS Makes Notable Cross Below Critical Moving Average
NASDAQ · 4d ago
Weekly Report: what happened at GRFS last week (0126-0130)?
Weekly Report · 02/02 10:31
White Falcon: Q4 2025 Portfolio Positions
Seeking Alpha · 01/27 02:15
Weekly Report: what happened at GRFS last week (0119-0123)?
Weekly Report · 01/26 10:31
Weekly Report: what happened at GRFS last week (0112-0116)?
Weekly Report · 01/19 10:38
Rigel Pharmaceuticals prelim Q4 revenue beats estimates
Reuters · 01/12 13:16
Weekly Report: what happened at GRFS last week (0105-0109)?
Weekly Report · 01/12 10:37
Grifols Adjusts Board Secretariat Roles Effective January 1, 2026
TipRanks · 01/08 20:47
Grifols Names Laura de la Cruz Galán as Board Secretary and Núria Martín Barnés as Vice-secretary
Reuters · 01/08 20:17
Grifols price target lowered to EUR 13.50 from EUR 15 at Barclays
TipRanks · 01/06 18:40
Weekly Report: what happened at GRFS last week (1229-0102)?
Weekly Report · 01/05 10:30
Weekly Report: what happened at GRFS last week (1222-1226)?
Weekly Report · 12/29/2025 10:29
Grifols: Solid Q3 Execution, But Cash Conversion And 2026 Risks Keep Us Neutral
Seeking Alpha · 12/28/2025 14:10
Weekly Report: what happened at GRFS last week (1215-1219)?
Weekly Report · 12/22/2025 10:29
Biotest AG and Grifols Receive FDA Approval for Fesilty Fibrinogen Therapy
Reuters · 12/19/2025 11:02
Grifols Secures FDA Approval for FESILTY Fibrinogen Concentrate for Congenital Fibrinogen Deficiency
Reuters · 12/19/2025 11:01
GRIFOLS - RECEIVES US FDA APPROVAL FOR NEW FIBRINOGEN CONCENTRATE, FESILTYTM (FIBRINOGEN, HUMAN-CHMT)
Reuters · 12/19/2025 11:01
Grifols Upgraded to ‘BB-’ by S&P Global Ratings
Reuters · 12/17/2025 07:35
Grifols Achieves EMA Certification for Egyptian Plasma Operations
TipRanks · 12/16/2025 14:57
More
Webull provides a variety of real-time GRFS stock news. You can receive the latest news about Grifols S A through multiple platforms. This information may help you make smarter investment decisions.
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.